Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares Repurchased
Ratios

Dexcom (DXCM) Accumulated Depreciation & Amortization (2016 - 2025)

Dexcom (DXCM) has disclosed Accumulated Depreciation & Amortization for 16 consecutive years, with $39.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation & Amortization fell 1.0% to $39.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $39.5 million, a 1.0% decrease, with the full-year FY2025 number at $39.5 million, down 1.0% from a year prior.
  • Accumulated Depreciation & Amortization was $39.5 million for Q4 2025 at Dexcom, up from $28.1 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $466.3 million in Q3 2023 to a low of $9.2 million in Q1 2025.
  • A 5-year average of $65.1 million and a median of $39.9 million in 2024 define the central range for Accumulated Depreciation & Amortization.
  • Peak YoY movement for Accumulated Depreciation & Amortization: skyrocketed 289.88% in 2023, then tumbled 97.96% in 2024.
  • Dexcom's Accumulated Depreciation & Amortization stood at $102.0 million in 2021, then plummeted by 54.22% to $46.7 million in 2022, then fell by 10.28% to $41.9 million in 2023, then dropped by 4.77% to $39.9 million in 2024, then decreased by 1.0% to $39.5 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Accumulated Depreciation & Amortization are $39.5 million (Q4 2025), $28.1 million (Q3 2025), and $18.5 million (Q2 2025).